A review: Ketotifen in its treatment of allergic rhinitis (AR) and relevant disease

Zhuoran Wang

doi:10.54254/2753-8818/45/20240637

Research Article

Open access

Published on 26 July 2024

Download pdf

Wang,Z. (2024). A review: Ketotifen in its treatment of allergic rhinitis (AR) and relevant disease. Theoretical and Natural Science,45,340-345.

Export citation

A review: Ketotifen in its treatment of allergic rhinitis (AR) and relevant disease

Zhuoran Wang *^,1,

¹ Hunan Agricultural University

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2753-8818/45/20240637

Abstract

Allergic rhinitis (AR) is a common disease in the world, which causes various adverse effects on quality of life. There are over 1 billion AR patients globally, with over 300 million cases in China alone. AR is closely related to asthma, 70.3% of children with AR can develop to asthma, and 80-95% of asthmatics have AR. To address the correlation between these two diseases, in 2015, the World Health Organization (WHO) put forward the idea of “the same airway, the same disease”. Although a relatively low mortality rate, AR confers a significant burden on personal health and society. Ketotifen was an old medicine for asthma and AR etc., invented in 1970. In experiments with rat models and rat peritoneal mast cells, Ketotifen has been demonstrated to effectively inhibit histamine release induced by substances like 48/80. Ketotifen has been proven effective in treating AR and relevant diseases in clinics. We will review the mechanisms of ketotifen in treating AR for further study.

Keywords

Allergic rhinitis (AR), Ketotifen, asthma

View pdf

References

[1]. Dana V. Wallace, Mark S. Dykewicz, David I. Bernstein, Joann Blessing-Moore, Linda Cox, David A. Khan, David M. Lang, Richard A. Nicklas, John Oppenheimer, Jay M. Portnoy, Christopher C. Randolph, Diane Schuller, Sheldon L. Spector, Stephen A. Tilles, The diagnosis and management of rhinitis: An updated practice parameter, Journal of Allergy and Clinical Immunology, Volume 122, Issue 2, Supplement, 2008, Pages S1-S84, ISSN 0091-6749, https://doi.org/10.1016/j.jaci.2008.06.003.

[2]. Joos, G., Pauwels, R., & Van Der Straeten, M. (1987). The effect of sodium cromoglycate and nedocromil sodium on neuropeptide induced bronchoconstriction in the rat. Revista Espaniola de Alergologia e Immunologia, 2, 197.

[3]. McCrory DC, Williams JW, Dolor RJ, Gray RN, Kolimaga JT, Reed S, Sundy J, Witsell DL. Management of allergic rhinitis in the working-age population. Evid Rep Technol Assess (Summ). 2003 Jan;(67):1-4. PMID: 12674744; PMCID: PMC4781251.

[4]. Meltzer, E. O., Blaiss, M. S., Naclerio, R. M., Stoloff, S. W., Derebery, M. J., Nelson, H. S., Boyle, J. M., & Wingertzahn, M. A. (2012). Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy and asthma proceedings, 33 Suppl 1, S113–S141.https://doi.org/10.2500/aap.2012.33.3603

[5]. Blaiss, M. S., Meltzer, E. O., Derebery, M. J., & Boyle, J. M. (2007). Patient and healthcare-provider perspectives on the burden of allergic rhinitis. Allergy and asthma proceedings, 28 Suppl 1, S4–S10. https://doi.org/10.2500/aap.2007.28.2991

[6]. Wang XD, Zheng M, Lou HF, Wang CS, Zhang Y, Bo MY, Ge SQ, Zhang N, Zhang L, Bachert C. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy. 2016 Aug;71(8):1170-80. doi: 10.1111/all.12874. Epub 2016 Apr 13. PMID: 26948849; PMCID: PMC5074323.

[7]. Blaiss M. S. (2010). Allergic rhinitis: Direct and indirect costs. Allergy and asthma proceedings, 31(5), 375–380. https://doi.org/10.2500/aap.2010.31.3329

[8]. Bernstein, D. I., Schwartz, G., & Bernstein, J. A. (2016). Allergic Rhinitis: Mechanisms and Treatment. Immunology and allergy clinics of North America, 36(2), 261–278. https://doi.org/10.1016/j.iac.2015.12.004

[9]. Bernstein, J. A., & Moellman, J. J. (2012). Progress in the emergency management of hereditary angioedema: focus on new treatment options in the United States. Postgraduate medicine, 124(3), 91-100. doi: 10.3810/pgm.2012.05.2552. PMID: 22691903.

[10]. Eggleston, P. A. (2001). Methods and effectiveness of indoor environmental control. Annals of Allergy, Asthma & Immunology, 87(6), 44-47.

[11]. Ketotifen | CAS#:34580-13-7 | Chemsrc

[12]. Martin, U., & Roemer, D. (1977). Ketotifen, a new type of anti-anaphylactic agent. Allergol Immunopathol, 5(suppl), 5.

[13]. L.P. Craps, U.M. Ney; Ketotifen: Current Views on Its Mechanism of Action and Their Therapeutic Implications. Respiration 1 April 1984; 45 (4): 411–421. https://doi.org/10.1159/000194648

[14]. Grant, S.M., Goa, K.L., Fitton, A. et al. Ketotifen. Drugs 40, 412–448 (1990). https://doi.org/10.2165/00003495-199040030-00006

[15]. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 548. ISBN 9783527607495.

[16]. “Zaditor- ketotifen fumarate solution”. DailyMed. 13 February 2020. Retrieved 4 September 2020.

[17]. Grant, S.M., Goa, K.L., Fitton, A. et al. Ketotifen. Drugs 40, 412–448 (1990). https://doi.org/10.2165/00003495-199040030-00006

[18]. Phillips MJ. Meyrick Thomas RH. Moodley I. Davies RJ. A comparison of the in vivo effects of ketotifen. c1emastine. chlorpheniramine and sodium cromoglycate on histamine and allergen induced weals in human skin. British Journal of Clinical Pharmacology 15: 277-286. 1983

Cite this article

Wang,Z. (2024). A review: Ketotifen in its treatment of allergic rhinitis (AR) and relevant disease. Theoretical and Natural Science,45,340-345.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 2nd International Conference on Modern Medicine and Global Health

Conference website: https://www.icmmgh.org/

ISBN：978-1-83558-551-1(Print) / 978-1-83558-552-8(Online)

Conference date: 5 January 2024

Editor：Mohammed JK Bashir

Series: Theoretical and Natural Science

Volume number: Vol.45

ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).